Clinical trials further support the potential of RIPostC to enhance recovery in patients with stroke, as evidenced by improved NIHSS scores, reduced high-sensitivity (hs)-CRP levels, diminished brain tissue infarct volume, and enhanced cognitive function post-stroke [21–25]. The gene discussed is CRP; the disease is stroke disorder.